Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This study found that scalp hypothermia effectively prevented chemotherapy-induced alopecia in 57.3% of breast cancer patients, with side effects such as a feeling of cold and slight headaches reported in 16% of cases.

In this study, researchers found that using the Orbis II scalp cooling device in a single-center setting effectively prevented severe chemotherapy-induced alopecia in 73% of patients with various cancer types, though the authors recommend further studies to explore broader applicability and influencing factors.

This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.